Tag: carbapenem-resistant Enterobacterales
-
Colistin Monotherapy vs Colistin-Meropenem in CRE Acquisition: AIDA Trial Findings
Background and Rationale Carbapenem-resistant Enterobacterales (CRE) pose a growing threat in healthcare settings due to limited treatment options and high mortality. Colistin, often used as a backbone of therapy, is frequently combined with carbapenems like meropenem in attempts to broaden antimicrobial activity and suppress resistance. The AIDA randomized trial investigates whether colistin monotherapy or a…
-
CRE Acquisition After Colistin Monotherapy vs Colistin-Meropenem: Insights from the AIDA Trial
Overview Carbapenem-resistant Enterobacterales (CRE) infections pose a major challenge across healthcare settings due to limited treatment options and high mortality. The AIDA randomized trial investigates how initial treatment choices—specifically colistin monotherapy versus a combination of colistin with meropenem—may influence subsequent acquisition and molecular characteristics of CRE isolates. This article summarizes the study’s aims, methods, key…
-
Colistin-Based Strategies Against CRE: Insights from the AIDA Randomized Trial on Acquisition and Molecular Traits after Monotherapy vs. Colistin-Meropenem Therapy
Overview: Why the AIDA Trial Matters for CRE Management Carbapenem-resistant Enterobacterales (CRE) pose a critical challenge in modern medicine, limiting effective treatment options and driving higher mortality. In the ongoing effort to optimize therapy, clinicians frequently employ colistin-based regimens, either as monotherapy or in combination with meropenem. The AIDA randomized trial investigates how these regimens…